Radiation and drug combination for liver cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer).
- Your liver cancer should be at a stage that could be removed with surgery (Stage IB to IIIA).
- You must not have had any systemic (whole-body) cancer treatment before joining this trial.
- You need to be in reasonably good physical shape (able to care for yourself and do daily activities).
- You must not have had major bleeding, blood clots, or serious stomach problems in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of two drugs (benmelstobart and anlotinib) plus a precise form of radiation (SBRT) for people with liver cancer that has spread a little and has already stopped responding to first-line treatment. The goal is to see if this combination can help control the cancer better.
This trial tests combining an immunotherapy drug (sintilimab) with targeted radiation therapy before surgery to shrink liver tumors and improve the chances of successful removal. It is designed for people with resectable liver cancer who have not yet had systemic treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.